1. Home
  2. NVA vs IFRX Comparison

NVA vs IFRX Comparison

Compare NVA & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVA
  • IFRX
  • Stock Information
  • Founded
  • NVA 1987
  • IFRX 2007
  • Country
  • NVA Australia
  • IFRX Germany
  • Employees
  • NVA N/A
  • IFRX N/A
  • Industry
  • NVA
  • IFRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • NVA
  • IFRX Health Care
  • Exchange
  • NVA NYSE
  • IFRX Nasdaq
  • Market Cap
  • NVA 65.4M
  • IFRX 65.8M
  • IPO Year
  • NVA N/A
  • IFRX 2017
  • Fundamental
  • Price
  • NVA $12.56
  • IFRX $0.79
  • Analyst Decision
  • NVA
  • IFRX Strong Buy
  • Analyst Count
  • NVA 0
  • IFRX 4
  • Target Price
  • NVA N/A
  • IFRX $7.75
  • AVG Volume (30 Days)
  • NVA 15.8K
  • IFRX 346.2K
  • Earning Date
  • NVA 01-01-0001
  • IFRX 08-07-2025
  • Dividend Yield
  • NVA N/A
  • IFRX N/A
  • EPS Growth
  • NVA N/A
  • IFRX N/A
  • EPS
  • NVA N/A
  • IFRX N/A
  • Revenue
  • NVA N/A
  • IFRX $140,242.00
  • Revenue This Year
  • NVA N/A
  • IFRX N/A
  • Revenue Next Year
  • NVA N/A
  • IFRX $6,309.47
  • P/E Ratio
  • NVA N/A
  • IFRX N/A
  • Revenue Growth
  • NVA N/A
  • IFRX 30.90
  • 52 Week Low
  • NVA $4.35
  • IFRX $0.71
  • 52 Week High
  • NVA $19.00
  • IFRX $2.82
  • Technical
  • Relative Strength Index (RSI)
  • NVA N/A
  • IFRX 35.74
  • Support Level
  • NVA N/A
  • IFRX $0.77
  • Resistance Level
  • NVA N/A
  • IFRX $0.83
  • Average True Range (ATR)
  • NVA 0.00
  • IFRX 0.05
  • MACD
  • NVA 0.00
  • IFRX 0.02
  • Stochastic Oscillator
  • NVA 0.00
  • IFRX 35.40

About NVA NOVA MINERALS LTD SPON ADS EACH REP 60 ORD

Nova Minerals Ltd is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project. It includes projects such as Estelle Gold and Critical Minerals Project, RPM, Korbel, Train and Stoney. It operates in one segment which is exploration of minerals and two geographical areas, being Australia and United States, where Australia derives maximum revenue.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: